CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration, according to a presentation at the American Society of Retina Specialists annual meeting.
“When we start thinking about the current demand and what we actually need for patients with wet macular degeneration, there’s a clear need for up to 40% of patients who don’t have full optimal treatment,” David Almeida, MD, MBA, PhD, of Erie Retina Research in Pennsylvania, told Healio. “What do we do with those patients? This is where I think this phase 1 study really becomes interesting and